Nordic Nanovector begins dosing in Phase I trial of Betalutin for DLBCL

Norwegian-based Nordic Nanovector has begun dosing patients in a Phase I clinical trial (LYMRIT 37-05) of Betalutin (177Lu-satetraxetan-lilotomab) to treat diffuse large B-cell lymphoma (DLBCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news